This marks the first time a GLP-1-based therapy has been approved for MASH (non-cirrhotic metabolic dysfunction-associated steatohepatitis), a progressive liver disease affecting roughly 5 percent of U.S. adults. The approval covers adults with moderate to advanced liver fibrosis (stages F2–F3), and treatment must be combined with a reduced-calorie diet and increased physical activity.
Wegovy approved in the U.S. for treatment of liver disease
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novo Nordisk’s drug Wegovy to treat the serious liver condition known as MASH. The decision strengthens the company’s position in the field of metabolic diseases.
By Ella Käck
Advertisement
BREAKING